Scientific Approach
Pipeline
INBRX-109
INBRX-106
INBRX-105
INBRX-101
Investors
Patients
Partners
Who We Are
Team
Contact Us
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Oct 20, 2022
Inhibrx Announces Participation in Upcoming Scientific Conferences
Aug 15, 2022
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
Aug 8, 2022
Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Jun 30, 2022
Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
May 19, 2022
Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting
May 12, 2022
Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency
May 9, 2022
Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Mar 24, 2022
Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting
Feb 28, 2022
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights
Feb 22, 2022
Inhibrx Announces Amended Loan Agreement with Oxford
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
»
